The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease
Open accessAbstract
The valine at position 82 (Val 82) in the active site of the human immunodeficiency virus (HIV) protease mutates in response to therapy with the protease inhibitor ritonavir. By using the X-ray crystal structure of the complex of HIV protease and ritonavir, the potent protease inhibitor ABT-378, which has a diminished interaction with Val 82, was designed. ABT-378 potently inhibited wild-type and mutant HIV protease ( K i = 1.3 to 3.6 pM), blocked the replication of laboratory and clinical strains of HIV type 1 (50% effective concentration [EC 50 ], 0.006 to 0.017 μM), and maintained high potency against mutant HIV selected by ritonavir in vivo (EC 50 , ≤0.06 μM). The metabolism of ABT-378 was strongly inhibited by ritonavir in vitro. Consequently, following concomitant oral administration of ABT-378 and ritonavir, the concentrations of ABT-378 in rat, dog, and monkey plasma exceeded the in vitro antiviral EC 50 in the presence of human serum by >50-fold after 8 h. In healthy human volunteers, coadministration of a single 400-mg dose of ABT-378 with 50 mg of ritonavir enhanced the area under the concentration curve of ABT-378 in plasma by 77-fold over that observed after dosing with ABT-378 alone, and mean concentrations of ABT-378 exceeded the EC 50 for >24 h. These results demonstrate the potential utility of ABT-378 as a therapeutic intervention against AIDS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,640
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J., & De Clercq, E. (1988) · Journal of Virological Methods · doi:10.1016/0166-0934(88)90134-6 · Cited by 1,642
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
Molla, A., Korneyeva, M., Gao, Q., Vasavanonda, S., Schipper, P. J., Mo, H.-M., Markowitz, M., Chernyavskiy, T., Niu, P., Lyons, N., et al. (1996) · Nature Medicine · doi:10.1038/nm0796-760 · Cited by 762
Self-citationNovel Fluorogenic Substrates for Assaying Retroviral Proteases by Resonance Energy Transfer
Matayoshi, E. D., Wang, G. T., Krafft, G. A., & Erickson, J. (1990) · Science · doi:10.1126/science.2106161 · Cited by 592
Danner, S. A., Carr, A., Leonard, J. M., Lehman, L. M., Gudiol, F., Gonzales, J., Raventos, A., Rubio, R., Bouza, E., Pintado, V., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332303 · Cited by 567
Self-citationKempf, D. J., Marsh, K. C., Denissen, J. F., McDonald, E., Vasavanonda, S., Flentge, C. A., Green, B. E., Fino, L., Park, C. H., & Kong, X. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2484 · Cited by 560
Self-citationRandomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
Cameron, D. W., Heath-Chiozzi, M., Danner, S., Cohen, C., Kravcik, S., Maurath, C., Sun, E., Henry, D., Rode, R., Potthoff, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)04161-5 · Cited by 536
Self-citationA Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection
Markowitz, M., Saag, M., Powderly, W. G., Hurley, A. M., Hsu, A., Valdes, J. M., Henry, D., Sattler, F., Marca, A. L., Leonard, J. M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332204 · Cited by 493
Self-citationKempf, D. J., Marsh, K. C., Kumar, G., Rodrigues, A. D., Denissen, J. F., McDonald, E., Kukulka, M. J., Hsu, A., Granneman, G. R., Baroldi, P. A., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.654 · Cited by 417
Self-citationKumar, G. N., Rodrigues, A. D., Buko, A. M., & Denissen, J. F. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12840-1 · Cited by 353
Self-citation
Cited by
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Choy, K.-T., Wong, A. Y.-L., Kaewpreedee, P., Sia, S. F., Chen, D., Hui, K. P. Y., Chu, D. K. W., Chan, M. C. W., Cheung, P. P.-H., Huang, X., et al. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104786 · Cited by 922
Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection
Walmsley, S., Bernstein, B., King, M., Arribas, J., Beall, G., Ruane, P., Johnson, M., Johnson, D., Lalonde, R., Japour, A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012354 · Cited by 647
Self-citationComputational methods in drug discovery
Leelananda, S. P., & Lindert, S. (2016) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.12.267 · Cited by 639
Sabe, V. T., Ntombela, T., Jhamba, L. A., Maguire, G. E. M., Govender, T., Naicker, T., & Kruger, H. G. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113705 · Cited by 625
In silico methods and tools for drug discovery
Shaker, B., Ahmad, S., Lee, J., Jung, C., & Na, D. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104851 · Cited by 607
Candidate drugs against SARS-CoV-2 and COVID-19
McKee, D. L., Sternberg, A., Stange, U., Laufer, S., & Naujokat, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104859 · Cited by 562
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs
Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M., & McLeod, H. L. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544030-00005 · Cited by 517
Dybul, M., Fauci, A. S., Bartlett, J. G., Kaplan, J. E., & Pau, A. K. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_2-200209031-00001 · Cited by 482
HIV-1 protease: mechanism and drug discovery
Brik, A., & Wong, C.-H. (2003) · Organic & Biomolecular Chemistry · doi:10.1039/b208248a · Cited by 455
HIV protease inhibitors: a review of molecular selectivity and toxicity
Wang, Y., Lv, Z., & Chu, Y. (2015) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s79956 · Cited by 450
Lopinavir/Ritonavir: A Review of its Use in the Management of HIV Infection
Cvetkovic, R. S., & Goa, K. L. (2003) · Drugs · doi:10.2165/00003495-200363080-00004 · Cited by 436
Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS
Ghosh, A. K., Osswald, H. L., & Prato, G. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01697 · Cited by 419
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic
Lythgoe, M. P., & Middleton, P. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.03.006 · Cited by 380
Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance
Wensing, A. M. J., van Maarseveen, N. M., & Nijhuis, M. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.003 · Cited by 339
Keynote review: Structural biology and drug discovery
Congreve, M., Murray, C. W., & Blundell, T. L. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03484-7 · Cited by 338
Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance
Shafer, R. W. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.2.247-277.2002 · Cited by 314
Alanagreh, L., Alzoughool, F., & Atoum, M. (2020) · Pathogens · doi:10.3390/pathogens9050331 · Cited by 291
Hou, T., & Yu, R. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0609162 · Cited by 261
Drugs, leads, and drug-likeness: an analysis of some recently launched drugs
Proudfoot, J. R. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00244-5 · Cited by 252
Retroviral proteases and their roles in virion maturation
Konvalinka, J., Kräusslich, H.-G., & Müller, B. (2015) · Virology · doi:10.1016/j.virol.2015.03.021 · Cited by 148
Metadata
- Authors
- Sham, H. L., Kempf, D. J., Molla, A., Marsh, K. C., Kumar, G. N., Chen, C.-M., Kati, W., Stewart, K., Lal, R., Hsu, A., Betebenner, D., Korneyeva, M., Vasavanonda, S., McDonald, E., Saldivar, A., Wideburg, N., Chen, X., Niu, P., Park, C., Jayanti, V., Grabowski, B., Granneman, G. R., Sun, E., Japour, A. J., Leonard, J. M., Plattner, J. J., & Norbeck, D. W.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1998-12
- Volume
- 42
- Issue
- 12
- Pages
- 3218-3224
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2112857740
- Cited by
- 471
- References
- 21
- FWCI
- 9.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.